Medable Selected by GSK to Power Decentralized and Hybrid Clinical Trials


Medable announced that it has entered a four-year enterprise contract with GSK to enable decentralized clinical trials (DCTs) across their portfolio using the company’s DCT platform. Medable was selected by GSK to accelerate the delivery of new medicines and enable their clinical trials to be more inclusive and representative of all patient populations.

Read more about the new partnership here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.